Nonalcoholic Fatty Liver Disease Management: Dietary and Lifestyle Modifications

Seminars in Liver Disease

Volumn 35, Issue 3, 2015, Pages 318-337

  Nguyen, Vi ^a   George, Jacob ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

dietary modification; exercise; lifestyle intervention; macronutrients; nonalcoholic fatty liver; nonalcoholic steatohepatitis

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; CARBOHYDRATE; CHOLESTEROL; FRUCTOSE; MONOUNSATURATED FATTY ACID; POLYUNSATURATED FATTY ACID; PROBIOTIC AGENT; SATURATED FATTY ACID; TRACE ELEMENT; TRANS FATTY ACID; VITAMIN D;

ARTICLE; CALORIC RESTRICTION; CALORIE; CANCER MORTALITY; CANCER PREVENTION; CLINICAL TRIAL (TOPIC); COFFEE; COGNITIVE THERAPY; DIABETES MELLITUS; DIET; GLYCEMIC INDEX; HEPATITIS; HUMAN; INTESTINE FLORA; LIFESTYLE MODIFICATION; LIVER INJURY; LIVER TRANSPLANTATION; LOW CARBOHYDRATE DIET; MACRONUTRIENT; MEDITERRANEAN DIET; META ANALYSIS (TOPIC); MOLECULAR RECOGNITION; MULTICENTER STUDY (TOPIC); NONALCOHOLIC FATTY LIVER; NONHUMAN; NUTRIENT; OUTCOME ASSESSMENT; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESISTANCE TRAINING; SYSTEMIC DISEASE; WEIGHT REDUCTION; ADVERSE EFFECTS; ATTITUDE TO HEALTH; CALORIC INTAKE; DISEASE COURSE; EXERCISE; HEALTH BEHAVIOR; LIFESTYLE; NON-ALCOHOLIC FATTY LIVER DISEASE; NUTRITIONAL STATUS; PSYCHOLOGY; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SEDENTARY LIFESTYLE; TREATMENT OUTCOME;

COGNITIVE THERAPY; DIET; DISEASE PROGRESSION; ENERGY INTAKE; EXERCISE; HEALTH BEHAVIOR; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; LIFE STYLE; NON-ALCOHOLIC FATTY LIVER DISEASE; NUTRITIONAL STATUS; RISK ASSESSMENT; RISK FACTORS; RISK REDUCTION BEHAVIOR; SEDENTARY LIFESTYLE; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84941920973     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0035-1562950     Document Type: Article

References (225)

1. Argo C. K., Caldwell S. H. Epidemiology and natural history of non-alcoholic steatohepatitis. Clin Liver Dis: 2009; 13 4 511 531
2. Bellentani S., Scaglioni F., Marino M., Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis: 2010; 28 1 155 161
3. Ekstedt M., Franzén L. E., Mathiesen U. L., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology: 2006; 44 4 865 873
4. White D. L., Kanwal F., El-Serag H. B. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol: 2012; 10 12 1342 1359.e2
5. Adams L. A., Lymp J. F., St Sauver J., et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology: 2005; 129 1 113 121
6. Lazo M., Hernaez R., Bonekamp S., et al. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ: 2011; 343 d6891
7. Mahady S. E., George J. Management of nonalcoholic steatohepatitis: an evidence-based approach. Clin Liver Dis: 2012; 16 3 631 645
8. Avery L., Flynn D., van Wersch A., Sniehotta F. F., Trenell M. I. Changing physical activity behavior in type 2 diabetes: a systematic review and meta-analysis of behavioral interventions. Diabetes Care: 2012; 35 12 2681 2689
9. Butryn M. L., Webb V., Wadden T. A. Behavioral treatment of obesity. Psychiatr Clin North Am: 2011; 34 4 841 859
10. Boutelle K. N., Kirschenbaum D. S. Further support for consistent self-monitoring as a vital component of successful weight control. Obes Res: 1998; 6 3 219 224
11. Renjilian D. A., Perri M. G., Nezu A. M., McKelvey W. F., Shermer R. L., Anton S. D. Individual versus group therapy for obesity: effects of matching participants to their treatment preferences. J Consult Clin Psychol: 2001; 69 4 717 721
12. Wing R. R., Tate D. F., Gorin A. A., Raynor H. A., Fava J. L. A self-regulation program for maintenance of weight loss. N Engl J Med: 2006; 355 15 1563 1571
13. Moscatiello S., Di Luzio R., Bugianesi E., et al. Cognitive-behavioral treatment of nonalcoholic fatty liver disease: a propensity score-adjusted observational study. Obesity (Silver Spring): 2011; 19 4 763 770
14. Frith J., Day C. P., Robinson L., Elliott C., Jones D. E., Newton J. L. Potential strategies to improve uptake of exercise interventions in non-alcoholic fatty liver disease. J Hepatol: 2010; 52 1 112 116
15. Bellentani S., Dalle Grave R., Suppini A., Marchesini G.; Fatty Liver Italian Network. Behavior therapy for nonalcoholic fatty liver disease: the need for a multidisciplinary approach. Hepatology: 2008; 47 2 746 754
16. Newton J. L., Jones D. E., Henderson E., et al. Fatigue in non-alcoholic fatty liver disease (NAFLD) is significant and associates with inactivity and excessive daytime sleepiness but not with liver disease severity or insulin resistance. Gut: 2008; 57 6 807 813
17. Marchesini G., Nuccitelli G., Centis E., et al. Behavioral aspects of nonalcoholic fatty liver disease: diet, causes, and treatment. In Preedy V. R., Watson R. R., Martin C. R., Eds. Handbook of Behavior, Food and Nutrition. New York Springer: 2011; 1833 1844
18. Byrne S., Cooper Z., Fairburn C. Weight maintenance and relapse in obesity: a qualitative study. Int J Obes Relat Metab Disord: 2003; 27 8 955 962
19. Visram S., Crosland A., Cording H. Triggers for weight gain and loss among participants in a primary care-based intervention. Br J Community Nurs: 2009; 14 11 495 501
20. Phelan S., Hill J. O., Lang W., Dibello J. R., Wing R. R. Recovery from relapse among successful weight maintainers. Am J Clin Nutr: 2003; 78 6 1079 1084
21. Knowler W. C., Barrett-Connor E., Fowler S. E., et al. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med: 2002; 346 6 393 403
22. Lindström J., Louheranta A., Mannelin M., et al. Finnish Diabetes Prevention Study Group. The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care: 2003; 26 12 3230 3236
23. Sesso H. D., Paffenbarger R. S. Jr, Lee I. M. Physical activity and coronary heart disease in men: the Harvard Alumni Health Study. Circulation: 2000; 102 9 975 980
24. Wei M., Kampert J. B., Barlow C. E., et al. Relationship between low cardiorespiratory fitness and mortality in normal-weight, overweight, and obese men. JAMA: 1999; 282 16 1547 1553
25. Knowler W. C., Fowler S. E., Hamman R. F., et al. Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet: 2009; 374 9702 1677 1686
26. Diabetes Prevention Program Research Group The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS. Diabetes Care: 2012; 35 4 723 730
27. Pan X. R., Li G. W., Hu Y. H., et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care: 1997; 20 4 537 544
28. Gong Q., Gregg E. W., Wang J., et al. Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia: 2011; 54 2 300 307
29. Li G., Zhang P., Wang J., et al. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. Lancet Diabetes Endocrinol: 2014; 2 6 474 480
30. Kim D., Kim W. R., Kim H. J., Therneau T. M. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology: 2013; 57 4 1357 1365
31. Thoma C., Day C. P., Trenell M. I. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. J Hepatol: 2012; 56 1 255 266
32. Promrat K., Kleiner D. E., Niemeier H. M., et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology: 2010; 51 1 121 129
33. Eckard C., Cole R., Lockwood J., et al. Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial. Therap Adv Gastroenterol: 2013; 6 4 249 259
34. Vilar Gomez E., Rodriguez De Miranda A., Gra Oramas B., et al. Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther: 2009; 30 10 999 1009
35. Bugianesi E., Moscatiello S., Ciaravella M. F., Marchesini G. Insulin resistance in nonalcoholic fatty liver disease. Curr Pharm Des: 2010; 16 17 1941 1951
36. Marchesini G., Brizi M., Morselli-Labate A. M., et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med: 1999; 107 5 450 455
37. Calle E. E., Rodriguez C., Walker-Thurmond K., Thun M. J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med: 2003; 348 17 1625 1638
38. Arem H., Moore S. C., Park Y., et al. Physical activity and cancer-specific mortality in the NIH-AARP Diet and Health Study cohort. Int J Cancer: 2014; 135 2 423 431
39. Kampert J. B., Blair S. N., Barlow C. E., Kohl H. W. III. Physical activity, physical fitness, and all-cause and cancer mortality: a prospective study of men and women. Ann Epidemiol: 1996; 6 5 452 457
40. Wen C. P., Wai J. P., Tsai M. K., et al. Minimum amount of physical activity for reduced mortality and extended life expectancy: a prospective cohort study. Lancet: 2011; 378 9798 1244 1253
41. Ballard-Barbash R., Friedenreich C. M., Courneya K. S., Siddiqi S. M., McTiernan A., Alfano C. M. Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review. J Natl Cancer Inst: 2012; 104 11 815 840
42. Courneya K. S. Exercise in cancer survivors: an overview of research. Med Sci Sports Exerc: 2003; 35 11 1846 1852
43. Watson K., Baar K. mTOR and the health benefits of exercise. Semin Cell Dev Biol: 2014; 36 130 139
44. de Lorgeril M., Salen P. New insights into the health effects of dietary saturated and omega-6 and omega-3 polyunsaturated fatty acids. BMC Med: 2012; 10 50
45. Grosso G., Buscemi S., Galvano F., et al. Mediterranean diet and cancer: epidemiological evidence and mechanism of selected aspects. BMC Surg: 2013; 13 02 S14
46. de Lorgeril M., Salen P. The Mediterranean diet: rationale and evidence for its benefit. Curr Atheroscler Rep: 2008; 10 6 518 522
47. Bamia C., Lagiou P., Buckland G., et al. Mediterranean diet and colorectal cancer risk: results from a European cohort. Eur J Epidemiol: 2013; 28 4 317 328
48. Praud D., Bertuccio P., Bosetti C., Turati F., Ferraroni M., La Vecchia C. Adherence to the Mediterranean diet and gastric cancer risk in Italy. Int J Cancer: 2014; 134 12 2935 2941
49. Bosetti C., Turati F., Dal Pont A., et al. The role of Mediterranean diet on the risk of pancreatic cancer. Br J Cancer: 2013; 109 5 1360 1366
50. Turati F., Trichopoulos D., Polesel J., et al. Mediterranean diet and hepatocellular carcinoma. J Hepatol: 2014; 60 3 606 611
51. Buckland G., Travier N., Cottet V., et al. Adherence to the Mediterranean diet and risk of breast cancer in the European prospective investigation into cancer and nutrition cohort study. Int J Cancer: 2013; 132 12 2918 2927
52. Yang B., Ren X. L., Fu Y. Q., Gao J. L., Li D. Ratio of n-3/n-6 PUFAs and risk of breast cancer: a meta-analysis of 274135 adult females from 11 independent prospective studies. BMC Cancer: 2014; 14 105
53. Wang J., John E. M., Ingles S. A. 5-lipoxygenase and 5-lipoxygenase-activating protein gene polymorphisms, dietary linoleic acid, and risk for breast cancer. Cancer Epidemiol Biomarkers Prev: 2008; 17 10 2748 2754
54. Ravnskov U., McCully K. S., Rosch P. J. The statin-low cholesterol-cancer conundrum. QJM: 2012; 105 4 383 388
55. Sacks F. M., Pfeffer M. A., Moye L. A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med: 1996; 335 14 1001 1009
56. American Diabetes Association Standards of medical care in diabetes-2013. Diabetes Care: 2013; 36 01 S11 S66
57. Harrison S. A., Fecht W., Brunt E. M., Neuschwander-Tetri B. A. Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology: 2009; 49 1 80 86
58. Suzuki A., Lindor K., St Saver J., et al. Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. J Hepatol: 2005; 43 6 1060 1066
59. Solon-Biet S. M., McMahon A. C., Ballard J. W., et al. The ratio of macronutrients, not caloric intake, dictates cardiometabolic health, aging, and longevity in ad libitum-fed mice. Cell Metab: 2014; 19 3 418 430
60. Sorensen A., Mayntz D., Raubenheimer D., Simpson S. J. Protein-leverage in mice: the geometry of macronutrient balancing and consequences for fat deposition. Obesity (Silver Spring): 2008; 16 3 566 571
61. Kapahi P., Chen D., Rogers A. N., et al. With TOR, less is more: a key role for the conserved nutrient-sensing TOR pathway in aging. Cell Metab: 2010; 11 6 453 465
62. Fontana L., Partridge L., Longo V. D. Extending healthy life span-from yeast to humans. Science: 2010; 328 5976 321 326
63. Sacks F. M., Bray G. A., Carey V. J., et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med: 2009; 360 9 859 873
64. Ioannou G. N., Morrow O. B., Connole M. L., Lee S. P. Association between dietary nutrient composition and the incidence of cirrhosis or liver cancer in the United States population. Hepatology: 2009; 50 1 175 184
65. Sathiaraj E., Chutke M., Reddy M. Y., et al. A case-control study on nutritional risk factors in non-alcoholic fatty liver disease in Indian population. Eur J Clin Nutr: 2011; 65 4 533 537
66. Volynets V., Küper M. A., Strahl S., et al. Nutrition, intestinal permeability, and blood ethanol levels are altered in patients with nonalcoholic fatty liver disease (NAFLD). Dig Dis Sci: 2012; 57 7 1932 1941
67. Musso G., Gambino R., De Michieli F., et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology: 2003; 37 4 909 916
68. Cortez-Pinto H., Jesus L., Barros H., Lopes C., Moura M. C., Camilo M. E. How different is the dietary pattern in non-alcoholic steatohepatitis patients? Clin Nutr: 2006; 25 5 816 823
69. Toshimitsu K., Matsuura B., Ohkubo I., et al. Dietary habits and nutrient intake in non-alcoholic steatohepatitis. Nutrition: 2007; 23 1 46 52
70. Kang H., Greenson J. K., Omo J. T., et al. Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD. Am J Gastroenterol: 2006; 101 10 2247 2253
71. Kwon O. W., Jun D. W., Lee S. M., et al. Carbohydrate but not fat is associated with elevated aminotransferases. Aliment Pharmacol Ther: 2012; 35 9 1064 1072
72. Da Silva H. E., Arendt B. M., Noureldin S. A., Therapondos G., Guindi M., Allard J. P. A cross-sectional study assessing dietary intake and physical activity in Canadian patients with nonalcoholic fatty liver disease vs healthy controls. J Acad Nutr Diet: 2014; 114 8 1181 1194
73. Zelber-Sagi S., Nitzan-Kaluski D., Goldsmith R., et al. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. J Hepatol: 2007; 47 5 711 717
74. Simonen P., Kotronen A., Hallikainen M., et al. Cholesterol synthesis is increased and absorption decreased in non-alcoholic fatty liver disease independent of obesity. J Hepatol: 2011; 54 1 153 159
75. Min H. K., Kapoor A., Fuchs M., et al. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab: 2012; 15 5 665 674
76. Simonen M., Männistö V., Leppänen J., et al. Desmosterol in human nonalcoholic steatohepatitis. Hepatology: 2013; 58 3 976 982
77. Mozaffarian D., Katan M. B., Ascherio A., Stampfer M. J., Willett W. C. Trans fatty acids and cardiovascular disease. N Engl J Med: 2006; 354 15 1601 1613
78. Mozaffarian D. Trans fatty acids - effects on systemic inflammation and endothelial function. Atheroscler Suppl: 2006; 7 2 29 32
79. Mozaffarian D., de Oliveira Otto M. C., Lemaitre R. N., et al. trans-Palmitoleic acid, other dairy fat biomarkers, and incident diabetes: the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Clin Nutr: 2013; 97 4 854 861
80. Obara N., Fukushima K., Ueno Y., et al. Possible involvement and the mechanisms of excess trans-fatty acid consumption in severe NAFLD in mice. J Hepatol: 2010; 53 2 326 334
81. Neuschwander-Tetri B. A., Ford D. A., Acharya S., et al. Dietary trans-fatty acid induced NASH is normalized following loss of trans-fatty acids from hepatic lipid pools. Lipids: 2012; 47 10 941 950
82. Kris-Etherton P. M., Lefevre M., Mensink R. P., Petersen B., Fleming J., Flickinger B. D. Trans fatty acid intakes and food sources in the U.S. population: NHANES 1999-2002. Lipids: 2012; 47 10 931 940
83. Krauss R. M., Eckel R. H., Howard B., et al. AHA Dietary Guidelines: revision 2000: a statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Circulation: 2000; 102 18 2284 2299
84. Wang D., Wei Y., Pagliassotti M. J. Saturated fatty acids promote endoplasmic reticulum stress and liver injury in rats with hepatic steatosis. Endocrinology: 2006; 147 2 943 951
85. Vessby B., Uusitupa M., Hermansen K., et al. KANWU Study. Substituting dietary saturated for monounsaturated fat impairs insulin sensitivity in healthy men and women: The KANWU Study. Diabetologia: 2001; 44 3 312 319
86. Chowdhury R., Warnakula S., Kunutsor S., et al. Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis. Ann Intern Med: 2014; 160 6 398 406
87. Jakobsen M. U., O'Reilly E. J., Heitmann B. L., et al. Major types of dietary fat and risk of coronary heart disease: a pooled analysis of 11 cohort studies. Am J Clin Nutr: 2009; 89 5 1425 1432
88. Mozaffarian D., Micha R., Wallace S. Effects on coronary heart disease of increasing polyunsaturated fat in place of saturated fat: a systematic review and meta-analysis of randomized controlled trials. PLoS Med: 2010; 7 3 e1000252
89. Rajaram S., Burke K., Connell B., Myint T., Sabaté J. A monounsaturated fatty acid-rich pecan-enriched diet favorably alters the serum lipid profile of healthy men and women. J Nutr: 2001; 131 9 2275 2279
90. Kris-Etherton P. M., Pearson T. A., Wan Y., et al. High-monounsaturated fatty acid diets lower both plasma cholesterol and triacylglycerol concentrations. Am J Clin Nutr: 1999; 70 6 1009 1015
91. Wheeler M. L., Dunbar S. A., Jaacks L. M., et al. Macronutrients, food groups, and eating patterns in the management of diabetes: a systematic review of the literature, 2010. Diabetes Care: 2012; 35 2 434 445
92. Schwingshackl L., Hoffmann G. Monounsaturated fatty acids and risk of cardiovascular disease: synopsis of the evidence available from systematic reviews and meta-analyses. Nutrients: 2012; 4 12 1989 2007
93. Li Z. Z., Berk M., McIntyre T. M., Feldstein A. E. Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearoyl-CoA desaturase. J Biol Chem: 2009; 284 9 5637 5644
94. Bozzetto L., Prinster A., Annuzzi G., et al. Liver fat is reduced by an isoenergetic MUFA diet in a controlled randomized study in type 2 diabetic patients. Diabetes Care: 2012; 35 7 1429 1435
95. Laaksonen D. E., Nyyssönen K., Niskanen L., Rissanen T. H., Salonen J. T. Prediction of cardiovascular mortality in middle-aged men by dietary and serum linoleic and polyunsaturated fatty acids. Arch Intern Med: 2005; 165 2 193 199
96. Djoussé L., Folsom A. R., Province M. A., Hunt S. C., Ellison R. C.; National Heart, Lung, and Blood Institute Family Heart Study. Dietary linolenic acid and carotid atherosclerosis: the National Heart, Lung, and Blood Institute Family Heart Study. Am J Clin Nutr: 2003; 77 4 819 825
97. Michas G., Micha R., Zampelas A. Dietary fats and cardiovascular disease: putting together the pieces of a complicated puzzle. Atherosclerosis: 2014; 234 2 320 328
98. Simopoulos A. P. Evolutionary aspects of diet, the omega-6/omega-3 ratio and genetic variation: nutritional implications for chronic diseases. Biomed Pharmacother: 2006; 60 9 502 507
99. Parker H. M., Johnson N. A., Burdon C. A., Cohn J. S., O'Connor H. T., George J. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol: 2012; 56 4 944 951
100. Hamazaki T., Okuyama H. The Japan Society for Lipid Nutrition recommends to reduce the intake of linoleic acid. A review and critique of the scientific evidence. World Rev Nutr Diet: 2003; 92 109 132
101. Simopoulos A. P. The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. Exp Biol Med (Maywood): 2008; 233 6 674 688
102. Wu J. H., Lemaitre R. N., King I. B., et al. Circulating omega-6 polyunsaturated fatty acids and total and cause-specific mortality: the Cardiovascular Health Study. Circulation: 2014; 130 15 1245 1253
103. De Caterina R. n-3 fatty acids in cardiovascular disease. N Engl J Med: 2011; 364 25 2439 2450
104. Roncaglioni M. C., Tombesi M., Avanzini F., et al. Risk and Prevention Study Collaborative Group. n-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med: 2013; 368 19 1800 1808
105. Joensen A. M., Overvad K., Dethlefsen C., et al. Marine n-3 polyunsaturated fatty acids in adipose tissue and the risk of acute coronary syndrome. Circulation: 2011; 124 11 1232 1238
106. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Lancet: 1999; 354 9177 447 455
107. Ghafoorunissa A., Ibrahim A., Natarajan S. Substituting dietary linoleic acid with alpha-linolenic acid improves insulin sensitivity in sucrose fed rats. Biochim Biophys Acta: 2005; 1733 1 67 75
108. Lombardo Y. B., Chicco A. G. Effects of dietary polyunsaturated n-3 fatty acids on dyslipidemia and insulin resistance in rodents and humans. A review. J Nutr Biochem: 2006; 17 1 1 13
109. Wijendran V., Hayes K. C. Dietary n-6 and n-3 fatty acid balance and cardiovascular health. Annu Rev Nutr: 2004; 24 597 615
110. Scorletti E., Bhatia L., McCormick K. G., et al. WELCOME Study. Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome∗ study. Hepatology: 2014; 60 4 1211 1221
111. Dasarathy S., Dasarathy J., Khiyami A., et al. Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis. J Clin Gastroenterol: 2015; 49 2 137 144
112. Sanyal A. J., Abdelmalek M. F., Suzuki A., Cummings O. W., Chojkier M.; EPE-A Study Group. No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterology: 2014; 147 2 377 84.e1
113. Kurabayashi T., Okada M., Tanaka K.; The Niigata Epadel Study Group. Eicosapentaenoic acid effect on hyperlipidemia in menopausal Japanese women. Obstet Gynecol: 2000; 96 4 521 528
114. Tanaka N., Sano K., Horiuchi A., Tanaka E., Kiyosawa K., Aoyama T. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J Clin Gastroenterol: 2008; 42 4 413 418
115. Tapsell L. C., Gillen L. J., Patch C. S., et al. Including walnuts in a low-fat/modified-fat diet improves HDL cholesterol-to-total cholesterol ratios in patients with type 2 diabetes. Diabetes Care: 2004; 27 12 2777 2783
116. Fink A., Rüfer C. E., Le Grandois J., et al. Dietary walnut oil modulates liver steatosis in the obese Zucker rat. Eur J Nutr: 2014; 53 2 645 660
117. Garg A., Bantle J. P., Henry R. R., et al. Effects of varying carbohydrate content of diet in patients with non-insulin-dependent diabetes mellitus. JAMA: 1994; 271 18 1421 1428
118. McLaughlin T., Abbasi F., Lamendola C., Yeni-Komshian H., Reaven G. Carbohydrate-induced hypertriglyceridemia: an insight into the link between plasma insulin and triglyceride concentrations. J Clin Endocrinol Metab: 2000; 85 9 3085 3088
119. Hudgins L. C., Hellerstein M., Seidman C., Neese R., Diakun J., Hirsch J. Human fatty acid synthesis is stimulated by a eucaloric low fat, high carbohydrate diet. J Clin Invest: 1996; 97 9 2081 2091
120. Paniagua J. A., Gallego de la Sacristana A., Romero I., et al. Monounsaturated fat-rich diet prevents central body fat distribution and decreases postprandial adiponectin expression induced by a carbohydrate-rich diet in insulin-resistant subjects. Diabetes Care: 2007; 30 7 1717 1723
121. Feinman R. D., Pogozelski W. K., Astrup A., et al. Dietary carbohydrate restriction as the first approach in diabetes management: critical review and evidence base. Nutrition: 2015; 31 1 1 13
122. Haufe S., Engeli S., Kast P., et al. Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects. Hepatology: 2011; 53 5 1504 1514
123. Ryan M. C., Abbasi F., Lamendola C., Carter S., McLaughlin T. L. Serum alanine aminotransferase levels decrease further with carbohydrate than fat restriction in insulin-resistant adults. Diabetes Care: 2007; 30 5 1075 1080
124. Assy N., Nasser G., Kamayse I., et al. Soft drink consumption linked with fatty liver in the absence of traditional risk factors. Can J Gastroenterol: 2008; 22 10 811 816
125. Ouyang X., Cirillo P., Sautin Y., et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol: 2008; 48 6 993 999
126. Elliott S. S., Keim N. L., Stern J. S., Teff K., Havel P. J. Fructose, weight gain, and the insulin resistance syndrome. Am J Clin Nutr: 2002; 76 5 911 922
127. Fields M., Lewis C. G., Lure M. D. Responses of insulin to oral glucose and fructose loads in marginally copper-deficient rats fed starch or fructose. Nutrition: 1996; 12 7-8 524 528
128. Martinez F. J., Rizza R. A., Romero J. C. High-fructose feeding elicits insulin resistance, hyperinsulinism, and hypertension in normal mongrel dogs. Hypertension: 1994; 23 4 456 463
129. Lê K. A., Ith M., Kreis R., et al. Fructose overconsumption causes dyslipidemia and ectopic lipid deposition in healthy subjects with and without a family history of type 2 diabetes. Am J Clin Nutr: 2009; 89 6 1760 1765
130. Johnston R. D., Stephenson M. C., Crossland H., et al. No difference between high-fructose and high-glucose diets on liver triacylglycerol or biochemistry in healthy overweight men. Gastroenterology: 2013; 145 5 1016 1025.e2
131. Ngo Sock E. T., Lê K. A., Ith M., Kreis R., Boesch C., Tappy L. Effects of a short-term overfeeding with fructose or glucose in healthy young males. Br J Nutr: 2010; 103 7 939 943
132. Silbernagel G., Machann J., Unmuth S., et al. Effects of 4-week very-high-fructose/glucose diets on insulin sensitivity, visceral fat and intrahepatic lipids: an exploratory trial. Br J Nutr: 2011; 106 1 79 86
133. Livesey G., Taylor R., Livesey H., Liu S. Is there a dose-response relation of dietary glycemic load to risk of type 2 diabetes? Meta-analysis of prospective cohort studies. Am J Clin Nutr: 2013; 97 3 584 596
134. Ma X. Y., Liu J. P., Song Z. Y. Glycemic load, glycemic index and risk of cardiovascular diseases: meta-analyses of prospective studies. Atherosclerosis: 2012; 223 2 491 496
135. Thomas D., Elliott E. J. Low glycaemic index, or low glycaemic load, diets for diabetes mellitus. Cochrane Database Syst Rev: 2009; 1 CD006296
136. Valtueña S., Pellegrini N., Ardigò D., et al. Dietary glycemic index and liver steatosis. Am J Clin Nutr: 2006; 84 1 136 142, quiz 268-269
137. Micha R., Wallace S. K., Mozaffarian D. Red and processed meat consumption and risk of incident coronary heart disease, stroke, and diabetes mellitus: a systematic review and meta-analysis. Circulation: 2010; 121 21 2271 2283
138. Fung T. T., van Dam R. M., Hankinson S. E., Stampfer M., Willett W. C., Hu F. B. Low-carbohydrate diets and all-cause and cause-specific mortality: two cohort studies. Ann Intern Med: 2010; 153 5 289 298
139. Bernstein A. M., Sun Q., Hu F. B., Stampfer M. J., Manson J. E., Willett W. C. Major dietary protein sources and risk of coronary heart disease in women. Circulation: 2010; 122 9 876 883
140. Bao Y., Han J., Hu F. B., et al. Association of nut consumption with total and cause-specific mortality. N Engl J Med: 2013; 369 21 2001 2011
141. Larsen T. M., Dalskov S. M., van Baak M., et al. Diet, Obesity, and Genes (Diogenes) Project. Diets with high or low protein content and glycemic index for weight-loss maintenance. N Engl J Med: 2010; 363 22 2102 2113
142. Aller E. E., Larsen T. M., Claus H., et al. Weight loss maintenance in overweight subjects on ad libitum diets with high or low protein content and glycemic index: the DIOGENES trial 12-month results. Int J Obes: 2014; 38 12 1511 1517
143. Shai I., Schwarzfuchs D., Henkin Y., et al. Dietary Intervention Randomized Controlled Trial (DIRECT) Group. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med: 2008; 359 3 229 241
144. Serra-Majem L., Roman B., Estruch R. Scientific evidence of interventions using the Mediterranean diet: a systematic review. Nutr Rev: 2006; 64 2 Pt 2 S27 S47
145. Estruch R., Ros E., Salas-Salvadó J., et al. PREDIMED Study Investigators. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med: 2013; 368 14 1279 1290
146. Trichopoulou A., Costacou T., Bamia C., Trichopoulos D. Adherence to a Mediterranean diet and survival in a Greek population. N Engl J Med: 2003; 348 26 2599 2608
147. Sofi F., Cesari F., Abbate R., Gensini G. F., Casini A. Adherence to Mediterranean diet and health status: meta-analysis. BMJ: 2008; 337 a1344
148. Ryan M. C., Itsiopoulos C., Thodis T., et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol: 2013; 59 1 138 143
149. Fraser A., Abel R., Lawlor D. A., Fraser D., Elhayany A. A modified Mediterranean diet is associated with the greatest reduction in alanine aminotransferase levels in obese type 2 diabetes patients: results of a quasi-randomised controlled trial. Diabetologia: 2008; 51 9 1616 1622
150. Trovato F. M., Catalano D., Martines G. F., Pace P., Trovato G. M. Mediterranean diet and non-alcoholic fatty liver disease: the need of extended and comprehensive interventions. Clin Nutr: 2015; 34 1 86 88
151. Kontogianni M. D., Tileli N., Margariti A., et al. Adherence to the Mediterranean diet is associated with the severity of non-alcoholic fatty liver disease. Clin Nutr: 2014; 33 4 678 683
152. Hung T., Sievenpiper J. L., Marchie A., Kendall C. W., Jenkins D. J. Fat versus carbohydrate in insulin resistance, obesity, diabetes and cardiovascular disease. Curr Opin Clin Nutr Metab Care: 2003; 6 2 165 176
153. Keys A., Menotti A., Karvonen M. J., et al. The diet and 15-year death rate in the seven countries study. Am J Epidemiol: 1986; 124 6 903 915
154. Kromhout D.; Seven Countries Study Research Group. Food consumption patterns in the Seven Countries Study. Ann Med: 1989; 21 3 237 238
155. Parola M., Muraca R., Dianzani I., et al. Vitamin E dietary supplementation inhibits transforming growth factor beta 1 gene expression in the rat liver. FEBS Lett: 1992; 308 3 267 270
156. Harrison S. A., Torgerson S., Hayashi P., Ward J., Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol: 2003; 98 11 2485 2490
157. Sanyal A. J., Chalasani N., Kowdley K. V., et al. NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med: 2010; 362 18 1675 1685
158. Lavine J. E., Schwimmer J. B., Van Natta M. L., et al. Nonalcoholic Steatohepatitis Clinical Research Network. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA: 2011; 305 16 1659 1668
159. Miller E. R. III, Pastor-Barriuso R., Dalal D., Riemersma R. A., Appel L. J., Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med: 2005; 142 1 37 46
160. Bjelakovic G., Nikolova D., Gluud L. L., Simonetti R. G., Gluud C. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev: 2008; 2 CD007176
161. Dietrich M., Jacques P. F., Pencina M. J., et al. Vitamin E supplement use and the incidence of cardiovascular disease and all-cause mortality in the Framingham Heart Study: Does the underlying health status play a role? Atherosclerosis: 2009; 205 2 549 553
162. Bjelakovic G., Gluud L. L., Nikolova D., et al. Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst Rev: 2014; 1 CD007470
163. Durup D., Jorgensen H. L., Christensen J., Schwarz P., Heegaard A. M., Lind B. A reverse J-shaped association of all-cause mortality with serum 25-hydroxyvitamin D in general practice: the CopD study. J Clin Endocrinol Metab: 2012; 97 8 2644 2652
164. Michaëlsson K., Baron J. A., Snellman G., et al. Plasma vitamin D and mortality in older men: a community-based prospective cohort study. Am J Clin Nutr: 2010; 92 4 841 848
165. Amer M., Qayyum R. Relationship between 25-hydroxyvitamin D and all-cause and cardiovascular disease mortality. Am J Med: 2013; 126 6 509 514
166. Ju S. Y., Jeong H. S., Kim H. Blood vitamin D status and metabolic syndrome in the general adult population: a dose-response meta-analysis. J Clin Endocrinol Metab: 2014; 99 3 1053 1063
167. Pittas A. G., Chung M., Trikalinos T., et al. Systematic review: vitamin D and cardiometabolic outcomes. Ann Intern Med: 2010; 152 5 307 314
168. Pittas A. G., Lau J., Hu F. B., Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab: 2007; 92 6 2017 2029
169. Seida J. C., Mitri J., Colmers I. N., et al. Clinical review: Effect of vitamin D3 supplementation on improving glucose homeostasis and preventing diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab: 2014; 99 10 3551 3560
170. Roth C. L., Elfers C. T., Figlewicz D. P., et al. Vitamin D deficiency in obese rats exacerbates nonalcoholic fatty liver disease and increases hepatic resistin and Toll-like receptor activation. Hepatology: 2012; 55 4 1103 1111
171. Manna P., Jain S. K. Vitamin D up-regulates glucose transporter 4 (GLUT4) translocation and glucose utilization mediated by cystathionine-γ-lyase (CSE) activation and H2S formation in 3T3L1 adipocytes. J Biol Chem: 2012; 287 50 42324 42332
172. Ding N., Yu R. T., Subramaniam N., et al. A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response. Cell: 2013; 153 3 601 613
173. Fedirko V., Duarte-Salles T., Bamia C., et al. Prediagnostic circulating vitamin D levels and risk of hepatocellular carcinoma in European populations: a nested case-control study. Hepatology: 2014; 60 4 1222 1230
174. Finkelmeier F., Kronenberger B., Köberle V., et al. Severe 25-hydroxyvitamin D deficiency identifies a poor prognosis in patients with hepatocellular carcinoma - a prospective cohort study. Aliment Pharmacol Ther: 2014; 39 10 1204 1212
175. Sharifi N., Amani R., Hajiani E., Cheraghian B. Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? A randomized clinical trial. Endocrine: 2014; 47 1 70 80
176. Freedman N. D., Park Y., Abnet C. C., Hollenbeck A. R., Sinha R. Association of coffee drinking with total and cause-specific mortality. N Engl J Med: 2012; 366 20 1891 1904
177. Catalano D., Martines G. F., Tonzuso A., Pirri C., Trovato F. M., Trovato G. M. Protective role of coffee in non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci: 2010; 55 11 3200 3206
178. Gutiérrez-Grobe Y., Chávez-Tapia N., Sánchez-Valle V., et al. High coffee intake is associated with lower grade nonalcoholic fatty liver disease: the role of peripheral antioxidant activity. Ann Hepatol: 2012; 11 3 350 355
179. Birerdinc A., Stepanova M., Pawloski L., Younossi Z. M. Caffeine is protective in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther: 2012; 35 1 76 82
180. Bambha K., Wilson L. A., Unalp A., et al. Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN). Coffee consumption in NAFLD patients with lower insulin resistance is associated with lower risk of severe fibrosis. Liver Int: 2014; 34 8 1250 1258
181. Molloy J. W., Calcagno C. J., Williams C. D., Jones F. J., Torres D. M., Harrison S. A. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology: 2012; 55 2 429 436
182. Johnson S., Koh W. P., Wang R., Govindarajan S., Yu M. C., Yuan J. M. Coffee consumption and reduced risk of hepatocellular carcinoma: findings from the Singapore Chinese Health Study. Cancer Causes Control: 2011; 22 3 503 510
183. Schnabl B., Brenner D. A. Interactions between the intestinal microbiome and liver diseases. Gastroenterology: 2014; 146 6 1513 1524
184. Paolella G., Mandato C., Pierri L., Poeta M., Di Stasi M., Vajro P. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease. World J Gastroenterol: 2014; 20 42 15518 15531
185. Eslamparast T., Poustchi H., Zamani F., Sharafkhah M., Malekzadeh R., Hekmatdoost A. Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. Am J Clin Nutr: 2014; 99 3 535 542
186. Lim S. S., Vos T., Flaxman A. D., et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet: 2012; 380 9859 2224 2260
187. Xu G., Sui X., Liu S., et al. Effects of insufficient physical activity on mortality and life expectancy in Jiangxi province of China, 2007-2010. PLoS ONE: 2014; 9 10 e109826
188. Franco O. H., de Laet C., Peeters A., Jonker J., Mackenbach J., Nusselder W. Effects of physical activity on life expectancy with cardiovascular disease. Arch Intern Med: 2005; 165 20 2355 2360
189. Hu F. B., Sigal R. J., Rich-Edwards J. W., et al. Walking compared with vigorous physical activity and risk of type 2 diabetes in women: a prospective study. JAMA: 1999; 282 15 1433 1439
190. Lynch J., Helmrich S. P., Lakka T. A., et al. Moderately intense physical activities and high levels of cardiorespiratory fitness reduce the risk of non-insulin-dependent diabetes mellitus in middle-aged men. Arch Intern Med: 1996; 156 12 1307 1314
191. Tanasescu M., Leitzmann M. F., Rimm E. B., Willett W. C., Stampfer M. J., Hu F. B. Exercise type and intensity in relation to coronary heart disease in men. JAMA: 2002; 288 16 1994 2000
192. Johnson N. A., Sachinwalla T., Walton D. W., et al. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology: 2009; 50 4 1105 1112
193. Shephard R. J., Johnson N. Effects of physical activity upon the liver. Eur J Appl Physiol: 2015; 115 1 1 46
194. Perseghin G., Lattuada G., De Cobelli F., et al. Habitual physical activity is associated with intrahepatic fat content in humans. Diabetes Care: 2007; 30 3 683 688
195. Goodpaster B. H., Katsiaras A., Kelley D. E. Enhanced fat oxidation through physical activity is associated with improvements in insulin sensitivity in obesity. Diabetes: 2003; 52 9 2191 2197
196. Kemp B. E., Mitchelhill K. I., Stapleton D., Michell B. J., Chen Z. P., Witters L. A. Dealing with energy demand: the AMP-activated protein kinase. Trends Biochem Sci: 1999; 24 1 22 25
197. Houten S. M., Auwerx J. PGC-1alpha: turbocharging mitochondria. Cell: 2004; 119 1 5 7
198. Lim J. Y., Oh M. A., Kim W. H., Sohn H. Y., Park S. I. AMP-activated protein kinase inhibits TGF-β-induced fibrogenic responses of hepatic stellate cells by targeting transcriptional coactivator p300. J Cell Physiol: 2012; 227 3 1081 1089
199. Zelber-Sagi S., Nitzan-Kaluski D., Goldsmith R., et al. Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study. Hepatology: 2008; 48 6 1791 1798
200. Krasnoff J. B., Painter P. L., Wallace J. P., Bass N. M., Merriman R. B. Health-related fitness and physical activity in patients with nonalcoholic fatty liver disease. Hepatology: 2008; 47 4 1158 1166
201. Kistler K. D., Brunt E. M., Clark J. M., Diehl A. M., Sallis J. F., Schwimmer J. B.; NASH CRN Research Group. Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am J Gastroenterol: 2011; 106 3 460 468, quiz 469
202. St George A., Bauman A., Johnston A., Farrell G., Chey T., George J. Independent effects of physical activity in patients with nonalcoholic fatty liver disease. Hepatology: 2009; 50 1 68 76
203. Hallsworth K., Fattakhova G., Hollingsworth K. G., et al. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut: 2011; 60 9 1278 1283
204. Zelber-Sagi S., Buch A., Yeshua H., et al. Effect of resistance training on non-alcoholic fatty-liver disease a randomized-clinical trial. World J Gastroenterol: 2014; 20 15 4382 4392
205. Bacchi E., Negri C., Targher G., et al. Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease (the RAED2 Randomized Trial). Hepatology: 2013; 58 4 1287 1295
206. Slentz C. A., Bateman L. A., Willis L. H., et al. Effects of aerobic vs. resistance training on visceral and liver fat stores, liver enzymes, and insulin resistance by HOMA in overweight adults from STRRIDE AT/RT. Am J Physiol Endocrinol Metab: 2011; 301 5 E1033 E1039
207. Davidson L. E., Hudson R., Kilpatrick K., et al. Effects of exercise modality on insulin resistance and functional limitation in older adults: a randomized controlled trial. Arch Intern Med: 2009; 169 2 122 131
208. Bateman L. A., Slentz C. A., Willis L. H., et al. Comparison of aerobic versus resistance exercise training effects on metabolic syndrome (from the Studies of a Targeted Risk Reduction Intervention Through Defined Exercise - STRRIDE-AT/RT). Am J Cardiol: 2011; 108 6 838 844
209. Baumgartner R. N. Body composition in healthy aging. Ann N Y Acad Sci: 2000; 904 437 448
210. Davison K. K., Ford E. S., Cogswell M. E., Dietz W. H. Percentage of body fat and body mass index are associated with mobility limitations in people aged 70 and older from NHANES III. J Am Geriatr Soc: 2002; 50 11 1802 1809
211. Frontera W. R., Hughes V. A., Fielding R. A., Fiatarone M. A., Evans W. J., Roubenoff R. Aging of skeletal muscle: a 12-yr longitudinal study. J Appl Physiol (1985): 2000; 88 4 1321 1326
212. Elia M., Ritz P., Stubbs R. J. Total energy expenditure in the elderly. Eur J Clin Nutr: 2000; 54 03 S92 S103
213. Gale C. R., Martyn C. N., Cooper C., Sayer A. A. Grip strength, body composition, and mortality. Int J Epidemiol: 2007; 36 1 228 235
214. Hong H. C., Hwang S. Y., Choi H. Y., et al. Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean Sarcopenic Obesity Study. Hepatology: 2014; 59 5 1772 1778
215. Nomura T., Ikeda Y., Nakao S., et al. Muscle strength is a marker of insulin resistance in patients with type 2 diabetes: a pilot study. Endocr J: 2007; 54 5 791 796
216. Ratziu V., Bellentani S., Cortez-Pinto H., Day C., Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol: 2010; 53 2 372 384
217. Villareal D. T., Banks M., Sinacore D. R., Siener C., Klein S. Effect of weight loss and exercise on frailty in obese older adults. Arch Intern Med: 2006; 166 8 860 866
218. Pattullo V., Duarte-Rojo A., Soliman W., et al. A 24-week dietary and physical activity lifestyle intervention reduces hepatic insulin resistance in the obese with chronic hepatitis C. Liver Int: 2013; 33 3 410 419
219. Astell-Burt T., Feng X., Kolt G. S. Is neighborhood green space associated with a lower risk of type 2 diabetes? Evidence from 267,072 Australians. Diabetes Care: 2014; 37 1 197 201
220. Astell-Burt T., Feng X., Kolt G. S. Green space is associated with walking and moderate-to-vigorous physical activity (MVPA) in middle-to-older-aged adults: findings from 203 883 Australians in the 45 and Up Study. Br J Sports Med: 2014; 48 5 404 406
221. Astell-Burt T., Feng X., Mavoa S., Badland H. M., Giles-Corti B. Do low-income neighbourhoods have the least green space? A cross-sectional study of Australia's most populous cities. BMC Public Health: 2014; 14 292
222. Parmenter K., Waller J., Wardle J. Demographic variation in nutrition knowledge in England. Health Educ Res: 2000; 15 2 163 174
223. Wardle J., Steptoe A. Socioeconomic differences in attitudes and beliefs about healthy lifestyles. J Epidemiol Community Health: 2003; 57 6 440 443
224. Academy of Medical Royal Colleges Measuring up the medical profession's prescription for the nation's obesity crisis. London Academy of Medical Royal Colleges: 2013
225. Williams R., Aspinall R., Bellis M., et al. Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. Lancet: 2014; 384 9958 1953 1997